According to Aeterna Zentaris's latest financial reports the company has a price-to-book ratio of 0.3640.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Year | P/B ratio | Change |
---|---|---|
2023-12-31 | 0.3439 | -20.42% |
2022-12-31 | 0.4321 | -47.15% |
2021-12-31 | 0.8176 | -59.31% |
2020-12-31 | 2.01 | -127.17% |
2019-12-31 | -7.40 | -128.78% |
2018-12-31 | 25.7 | -283.45% |
2017-12-31 | -14.0 | -307.71% |
2016-12-31 | 6.74 | 229.16% |
2015-12-31 | 2.05 | -23.78% |
2014-12-31 | 2.69 | -26.67% |
2013-12-31 | 3.67 | -140.67% |
2012-12-31 | -9.01 | -74.12% |
2011-12-31 | -34.8 | -401.89% |
2010-12-31 | 11.5 | 107.79% |
2009-12-31 | 5.55 | 357.41% |
2008-12-31 | 1.21 | 31.26% |
2007-12-31 | 0.9246 | -23.2% |
2006-12-31 | 1.20 | -51.34% |
2005-12-31 | 2.47 | 11.63% |
2004-12-31 | 2.22 | 74.14% |
2003-12-31 | 1.27 | -28.09% |
2002-12-31 | 1.77 |
Company | P/B ratio | differencediff. | Country |
---|---|---|---|
Novartis NVS | 4.30 | 1,081.87% | ๐จ๐ญ Switzerland |
Sanofi SNY | 1.42 | 288.84% | ๐ซ๐ท France |
Bristol-Myers Squibb BMY | 3.36 | 822.60% | ๐บ๐ธ USA |
Spectrum Pharmaceuticals
SPPI | 7.89 | 2,066.48% | ๐บ๐ธ USA |
Halozyme Therapeutics HALO | 59.3 | 16,191.45% | ๐บ๐ธ USA |